Huize Holding Limited — FY2019 Form 20-F
Reporting period: Fiscal year ended December 31, 2019. This is an annual report, not a standalone fourth-quarter filing; quarterly Q4 results are not provided clearly in the filing text. Financial statements are prepared under U.S. GAAP. The company operates an online insurance brokerage platform in China and does not underwrite insurance risk.
Financial and operating performance
| Metric | FY2019 | Prior comparable period / change |
|---|---|---|
| Operating revenue | RMB993.3 million (US$142.7 million) | RMB508.8 million in 2018; up 95.2% |
| Brokerage income | RMB982.1 million | RMB503.5 million in 2018; up about 95% |
| Operating profit | RMB1.6 million; 0.2% margin | RMB24.8 million in 2018 |
| Net profit | RMB15.0 million (US$2.2 million); 1.5% margin | RMB2.9 million in 2018 |
| Net loss attributable to common shareholders | RMB25.4 million | RMB27.5 million in 2018, reflecting preferred-share accretion and allocation |
| Operating cash flow | RMB118.0 million | RMB66.9 million in 2018 |
| Cash and cash equivalents | RMB88.1 million | RMB6.6 million at year-end 2018 |
| Restricted cash | RMB161.2 million | RMB145.6 million at year-end 2018 |
| Borrowings | RMB36.9 million short-term; no long-term borrowings reported at year-end | RMB24.3 million total short- and current long-term borrowings in 2018 |
Amounts are consolidated and in RMB unless otherwise noted. The audited statements report FY2019 net profit of RMB15.0 million (RMB14.9 million attributable to Huize); some narrative risk-factor text instead cites RMB12.1 million. The filing does not reconcile that difference, so investors should verify against the audited statements.
Gross written premiums facilitated rose to RMB2,014.3 million from RMB941.0 million in 2018. Life and health products generated 90.9% of revenue; long-term health products accounted for about 70.7% of GWP. The company had 6.3 million cumulative insurance clients and 70 active insurer partners at year-end.
Material changes versus 2018
- Revenue and GWP expanded sharply, with growth led by life and health insurance, particularly long-term health products.
- Operating costs and expenses rose 104.9% to RMB991.7 million, slightly faster than revenue. Channel fees in cost of revenue increased to RMB561.6 million from RMB285.7 million.
- General and administrative expense increased to RMB161.8 million from RMB46.2 million, mainly because share-based compensation rose to RMB95.0 million from RMB1.0 million. The compensation included a substantial award to the founder/CEO and employee awards.
- Operating profit fell to RMB1.6 million from RMB24.8 million despite higher revenue. Net profit increased, partly reflecting RMB12.7 million in “others, net,” primarily a government-confirmed office rent exemption.
- Operating cash flow increased, but included significant non-cash share-based compensation and favorable movements in payables; accounts receivable also increased by RMB72.0 million on the balance sheet.
Liquidity, capital structure and outlook
- Year-end current assets were RMB461.5 million and current liabilities RMB361.8 million. Restricted cash includes insurance premiums held for remittance and regulatory guarantee deposits; it is not freely available for general use. Accounts receivable were RMB180.4 million.
- Year-end total liabilities were RMB362.8 million, alongside RMB454.6 million of redeemable preferred shares classified as mezzanine equity and a RMB308.7 million shareholders’ deficit. Preferred shares carried redemption provisions if a qualifying IPO did not occur by December 31, 2020; the IPO completed in February 2020 and the filing’s pro forma balance sheet reflects conversion.
- Management said cash, cash equivalents and anticipated operating cash flows should cover working capital and capital expenditure needs for at least 12 months. No quantified revenue or earnings guidance was provided.
- The company reported FY2019 G&A and expense growth, reliance on channel partners and insurer partners, and concentration: its four largest insurer partners contributed 54.9% of revenue. Five leading products contributed 32.3% of brokerage income.
- Management identified COVID-19 disruption in early 2020, including office closures, remote work and reduced operating efficiency; the impact on 2020 revenue, collections and results could not be estimated. The company also warned of evolving Chinese insurance regulation, VIE-structure uncertainty, cybersecurity and data-protection risks, and currency and cash-transfer restrictions.
- Regulatory inspections had identified historical compliance issues, including misuse of insurance premium funds and premium collection by certain unlicensed partners. The company said it had returned misused funds, ended relevant unlicensed arrangements and was undertaking remediation; retrospective penalties remain possible.
- Disclosure controls were deemed ineffective at December 31, 2019 due to a material weakness: insufficient qualified U.S. GAAP and SEC-reporting personnel. Management planned remediation. The auditor’s report gave an unqualified opinion on the financial statements, but the filing notes that the auditor’s China work was not subject to PCAOB inspection.
Important facts for investors to verify
- Reconcile the conflicting narrative net-profit figure (RMB12.1 million) with audited net profit of RMB15.0 million, and distinguish company net income from the common-shareholder loss.
- Assess whether operating cash flow is sustainable after separating non-cash share compensation and working-capital movements, especially rising receivables and payables.
- Evaluate how much cash is unrestricted and accessible to the offshore parent, given restricted premium balances, VIE arrangements and PRC remittance controls.
- Track the remediation and potential regulatory consequences of disclosed historical compliance issues, and confirm the status and effects of online-insurance rule changes.
- Monitor dilution and recurring compensation expense from equity awards, as well as insurer, product and channel concentration.
- Review the material weakness remediation, COVID-19 effects on 2020 performance and collections, and the company’s dependence on its contractual VIE structure.